HU224964B1 - Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone - Google Patents
Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone Download PDFInfo
- Publication number
- HU224964B1 HU224964B1 HU0001094A HUP0001094A HU224964B1 HU 224964 B1 HU224964 B1 HU 224964B1 HU 0001094 A HU0001094 A HU 0001094A HU P0001094 A HUP0001094 A HU P0001094A HU 224964 B1 HU224964 B1 HU 224964B1
- Authority
- HU
- Hungary
- Prior art keywords
- acid
- naloxone
- derivatives
- stabilizer
- salts
- Prior art date
Links
- 229960004127 naloxone Drugs 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 12
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title claims abstract 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 230000006641 stabilisation Effects 0.000 title description 4
- 238000011105 stabilization Methods 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003381 stabilizer Substances 0.000 claims abstract description 20
- 238000006471 dimerization reaction Methods 0.000 claims abstract description 18
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 4
- -1 hydroxyl fatty acids Chemical class 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 13
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 10
- 235000010269 sulphur dioxide Nutrition 0.000 claims description 10
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 9
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 5
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 5
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 5
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 235000011007 phosphoric acid Nutrition 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- XRSKRSVTUVLURN-UHFFFAOYSA-N 1,3-benzodioxol-4-ol Chemical class OC1=CC=CC2=C1OCO2 XRSKRSVTUVLURN-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- 239000004305 biphenyl Substances 0.000 claims description 4
- 150000005682 diethyl carbonates Chemical class 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 150000002739 metals Chemical class 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000003016 phosphoric acids Chemical class 0.000 claims description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 3
- 239000004158 L-cystine Substances 0.000 claims description 3
- 235000019393 L-cystine Nutrition 0.000 claims description 3
- 150000001555 benzenes Chemical class 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 6
- 239000005711 Benzoic acid Substances 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims 3
- 235000010233 benzoic acid Nutrition 0.000 claims 3
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 claims 3
- 229940018557 citraconic acid Drugs 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 3
- 235000010199 sorbic acid Nutrition 0.000 claims 3
- 239000004334 sorbic acid Substances 0.000 claims 3
- 229940075582 sorbic acid Drugs 0.000 claims 3
- 229960002433 cysteine Drugs 0.000 claims 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 abstract description 6
- 235000010265 sodium sulphite Nutrition 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 44
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 15
- 229960005250 naloxone hydrochloride Drugs 0.000 description 13
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000003929 acidic solution Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000012286 potassium permanganate Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- UZMKEUDBWHMRBM-PLKIVWSFSA-N benzoic acid;(2e,4e)-hexa-2,4-dienoic acid Chemical compound C\C=C\C=C\C(O)=O.OC(=O)C1=CC=CC=C1 UZMKEUDBWHMRBM-PLKIVWSFSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940065778 narcan Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229930015710 phenanthrene alkaloid Natural products 0.000 description 1
- 150000002987 phenanthrenes Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229960001402 tilidine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Insulating Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Cereal-Derived Products (AREA)
- Detergent Compositions (AREA)
Claims (19)
- SZABADALMI IGÉNYPONTOK35 1. Eljárás naloxon és sói stabilizálására, különösen folyékony gyógyszerkészítmény formákban a transzdermális terápiás rendszerek (TTS) kivételével, azzal jellemezve, hogy a naloxonhoz és sóihoz a naxolon 2,2’-dinaloxonná történő dimerizációja gátlására a40 gyógyszerkészítmény-forma összes tömegére számítva 0,001-5,0 tömeg% mennyiségben szerves vagy szervetlen stabilizátort adunk.
- 2. Az 1. igénypont szerinti eljárás, azzal jellemezve, hogy stabilizátorként legalább egy vegyületet alkalma45 zunk a következők közül:kén-dioxid, az aszkorbinsav és származékai, a tokoferol és annak víz- és zsíroldható származékai, így például a Tokofersolan® vagy a tokoferol-acetát, az alkálifémek, alkáliföldfémek és más fémek szulfitjai50 és hidrogén-szulfitjai, PHB-észterek, BHA, BHT, gallátok, valamint rövid szénláncú zsírsavak, gyümölcssavak, foszforsavak, a szorbinsav és a benzoesav és ezek sói, észterei, származékai és izomer vegyületei, az aszkorbil-palmitát, lecitinek, hidroxilcso55 porttal egyszeresen vagy többszörösen helyettesített benzolszármazékok, az etilén-diamin-tetraecetsav és sói, citrakonsav, cisztein, L-cisztin, konidendrinek, dietil-karbonátok, metilén-dioxi-fenolok, kefalinok, β,β’-ditiopropionsav, a bifenil és más fenilszárma60 zékok.HU 224 964 Β1
- 3. Az 1. vagy 2. igénypont szerinti eljárás, azzal jellemezve, hogy stabilizátorként kén-dioxidot, kénessavat vagy annak alkálifém- vagy alkáliföldfémsóit alkalmazzuk.
- 4. Az 1. vagy 2. igénypont szerinti eljárás, azzal jellemezve, hogy stabilizátorként etilén-diamin-tetraecetsavat vagy sóit alkalmazzuk.
- 5. Az 1-4. igénypontok bármelyike szerinti eljárás, azzal jellemezve, hogy a stabilizálandó gyógyszerkészítmény-formák további segédanyagokat és hatóanyagokat tartalmaznak.
- 6. Az 1-5. igénypontok bármelyike szerinti eljárás, azzal jellemezve, hogy a stabilizátort a gyógyszerkészítmény-forma összes tömegére számítva 0,001-1,0 tömeg% mennyiségben alkalmazzuk.
- 7. Az 1-6. igénypontok bármelyike szerinti eljárás, azzal jellemezve, hogy a stabilizátort a gyógyszerkészítmény-forma összes tömegére számítva 0,001-0,5 tömeg% mennyiségben alkalmazzuk.
- 8. Naloxont vagy a naloxon valamely farmakológiailag elfogadható sóját tartalmazó folyékony gyógyszerkészítmény-forma, kivévec) a transzdermális terápiás rendszereket (TTS), ésd) a metil- és propil-parabént tartalmazó parenterális gyógyszerkészítmény-formákat, amely gyógyszerkészítmény-forma legalább egy, a naloxon dimerizációját gátló stabilizátort tartalmaz 0,001-5,0 tömeg% mennyiségben az anyagkeverék összes tömegére számítva.
- 9. A 8. igénypont szerinti gyógyszerkészítmény-forma, amely további segédanyagokat és hatóanyagokat tartalmaz.
- 10. A 8. vagy 9. igénypont szerinti gyógyszerkészítmény-forma, amely legalább egy stabilizátort tartalmaz a gyógyszerkészítmény-forma összes tömegére számítva 0,001-1,0 tömeg% mennyiségben.
- 11. A 9-10. igénypontok bármelyike szerinti gyógyszerkészítmény-forma, amely legalább egy stabilizátort tartalmaz a gyógyszerkészítmény-forma összes tömegére számítva 0,001-0,5 tömeg% mennyiségben.
- 12. A 9-11. igénypontok bármelyike szerinti gyógyszerkészítmény-forma, amely stabilizátorként legalább egy, a következő csoportba tartozó vegyületet tartalmaz:kén-dioxid, az aszkorbinsav és származékai, a tokoferol és annak víz- és zsíroldható származékai, így például a Tokofersolan® vagy a tokoferol-acetát, az alkálifémek és alkáliföldfémek és más fémek szulfitjai és hidrogén-szulfitjai, PHB-észterek, BHA, BHT, gallátok, valamint rövid szénláncú zsírsavak, gyümölcssavak, foszforsavak, a szorbinsav és a benzoesav és ezek sói, észterei, származékai és izomer vegyületei, az aszkorbil-palmitát, lecitinek, hidroxilcsoporttal egyszeresen vagy többszörösen helyettesített benzolszármazékok, az etilén-diamin-tetraecetsav és sói, citrakonsav, cisztein, L-cisztin, konidendrinek, dietil-karbonátok, metilén-dioxi-fenolok, kefalinok, β,β’-ditiopropionsav, a bifenil és más fenilszármazékok.
- 13. A 12. igénypont szerinti gyógyszerkészítmény-forma, amely stabilizátorként kén-dioxidot, kénessavat vagy a kénessav alkálifém- vagy alkáliföldfémsóját tartalmazza.
- 14. A 12. igénypont szerinti gyógyszerkészítmény-forma, amely stabilizátorként etilén-diamin-tetraecetsavat vagy annak valamely sóját tartalmazza.
- 15. Legalább egy vegyület alkalmazása a naloxon dimerizációjának gátlására a következők közül: kén-dioxid, az aszkorbinsav és származékai, a tokoferol és annak víz- és zsíroldható származékai, így például a Tokofersolan® vagy a tokoferol-acetát, az alkálifémek és alkáliföldfémek és más fémek szulfitjai és hidrogén-szulfitjai, PHB-észterek, BHA, BHT, gallátok, valamint rövid szénláncú zsírsavak, gyümölcssavak, foszforsavak, a szorbinsav és a benzoesav és ezek sói, észterei, származékai és izomer vegyületei, az aszkorbil-palmitát, lecitinek, hidroxilcsoporttal egyszeresen vagy többszörösen helyettesített benzolszármazékok, az etilén-diamin-tetraecetsav és sói, citrakonsav, cisztein, L-cisztin, konidendrinek, dietil-karbonátok, metilén-dioxi-fenolok, kefalinok, β,β’-ditiopropionsav, a bifenil és más fenilszármazékok.
- 16. A 15. igénypont szerinti anyagok valamelyikének alkalmazása naloxon dimerizációjának gátlására, ahol az anyag kén-dioxid vagy kénessav, vagy annak alkálifém- vagy alkáliföldfémsója.
- 17. A 15. igénypont szerinti anyagok valamelyikének alkalmazása naloxon dimerizációjának gátlására, ahol az anyag etilén-diamin-tetraecetsav vagy sója.
- 18. A 15-17. igénypontok bármelyike szerinti alkalmazás, ahol a dimerizációt folyékony gyógyszerkészítmény formában gátoljuk.
- 19. A 18. igénypont szerinti alkalmazás, ahol a gyógyszerkészítmény-forma további segédanyagokat és hatóanyagokat tartalmaz.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19705537 | 1997-02-14 | ||
| PCT/EP1998/000556 WO1998035679A1 (de) | 1997-02-14 | 1998-02-03 | Stabilisierung von naloxonhydrochlorid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0001094A2 HUP0001094A2 (hu) | 2000-09-28 |
| HUP0001094A3 HUP0001094A3 (en) | 2001-02-28 |
| HU224964B1 true HU224964B1 (en) | 2006-04-28 |
Family
ID=7820153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001094A HU224964B1 (en) | 1997-02-14 | 1998-02-03 | Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0880352B1 (hu) |
| AT (1) | ATE186643T1 (hu) |
| CZ (1) | CZ297951B6 (hu) |
| DE (1) | DE59800046D1 (hu) |
| ES (1) | ES2141631T3 (hu) |
| GR (1) | GR3032458T3 (hu) |
| HU (1) | HU224964B1 (hu) |
| PL (1) | PL190293B1 (hu) |
| SK (1) | SK282549B6 (hu) |
| WO (1) | WO1998035679A1 (hu) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE210983T1 (de) * | 1997-11-03 | 2002-01-15 | Stada Arzneimittel Ag | Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum |
| ES2412409T3 (es) | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
| JP2001526229A (ja) | 1997-12-22 | 2001-12-18 | ユーロ−セルティーク，エス．エイ． | オピオイド投薬剤形の乱用を防止する方法 |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| GEP20053614B (en) | 2000-02-08 | 2005-09-26 | Euro Celtique Sa | Compositions for Oral Administration Containing Opioid Agonist |
| CA2446550C (en) | 2001-05-11 | 2012-03-06 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
| WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
| AU2002323032B2 (en) | 2001-08-06 | 2005-02-24 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
| US20140271788A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| RU2004130441A (ru) | 2002-03-14 | 2005-05-20 | Еуро-Селтик, С.А. (Lu) | Композиции налтрексона гидрохлорида |
| CA2708900C (en) | 2002-04-05 | 2019-06-04 | Purdue Pharma | Pharmaceutical preparation containing oxycodone and naloxone |
| DK1551372T3 (en) | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
| PL2368554T3 (pl) | 2003-04-08 | 2015-05-29 | Progenics Pharm Inc | Preparaty farmaceutyczne zawierające metylonaltrekson |
| MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| EP2526932B1 (en) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Pharmaceutical composition |
| WO2008133330A1 (ja) | 2007-04-26 | 2008-11-06 | Toray Industries, Inc. | ４，５－エポキシモルヒナン誘導体を含有する安定な固形製剤 |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| TR201802379T4 (tr) | 2008-10-24 | 2018-03-21 | Toray Industries | 4,5-epoksimorfinan türevi içeren stabil tablet. |
| PT2405915T (pt) | 2009-03-10 | 2019-01-29 | Euro Celtique Sa | Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona |
| TWI605814B (zh) | 2010-03-11 | 2017-11-21 | 惠氏有限責任公司 | 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽 |
| JP5838199B2 (ja) | 2010-05-10 | 2016-01-06 | ユーロ−セルティーク エス．エイ． | 活性剤を含まない顆粒およびその顆粒を含む錠剤の製造 |
| MX344846B (es) | 2010-05-10 | 2017-01-10 | Euro-Celtique S A * | Combinacion de granulos cargados activos con activos adicionales. |
| CA2795324C (en) * | 2012-11-09 | 2015-07-14 | Purdue Pharma | Pharmaceutical compositions comprising hydromorphone and naloxone |
| EP3024461B1 (en) | 2013-07-23 | 2020-05-13 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| DE112014005175T5 (de) | 2013-11-13 | 2016-07-21 | Euro-Celtique S.A. | Hydromorphon und Naloxon für die Behandlung von Schmerzen und Opioid-Darm-Dysfunktions-Syndrom |
| CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US9642848B2 (en) * | 2014-07-08 | 2017-05-09 | Insys Development Company, Inc. | Sublingual naloxone spray |
| US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS276692B6 (cs) * | 1990-08-29 | 1992-07-15 | Z Presneho Strojirenstvi | Zařízení k řazení hřebíků v násypce plníce |
| JPH07267862A (ja) * | 1994-03-29 | 1995-10-17 | Sekisui Chem Co Ltd | 経皮吸収貼付剤 |
| DE4423850A1 (de) * | 1994-07-07 | 1996-01-11 | Labtec Gmbh | Transdermales therapeutisches System zur Applikation von Naloxon |
| DE69709646T2 (de) * | 1996-03-12 | 2002-08-14 | Alza Corp., Palo Alto | Zusammensetzung und dosisform mit einem opioid-antagonisten |
-
1998
- 1998-02-03 WO PCT/EP1998/000556 patent/WO1998035679A1/de active IP Right Grant
- 1998-02-03 PL PL98335249A patent/PL190293B1/pl unknown
- 1998-02-03 SK SK1092-99A patent/SK282549B6/sk not_active IP Right Cessation
- 1998-02-03 CZ CZ0289699A patent/CZ297951B6/cs not_active IP Right Cessation
- 1998-02-03 DE DE59800046T patent/DE59800046D1/de not_active Expired - Lifetime
- 1998-02-03 HU HU0001094A patent/HU224964B1/hu unknown
- 1998-02-03 ES ES98905128T patent/ES2141631T3/es not_active Expired - Lifetime
- 1998-02-03 AT AT98905128T patent/ATE186643T1/de active
- 1998-02-03 EP EP98905128A patent/EP0880352B1/de not_active Expired - Lifetime
-
2000
- 2000-01-25 GR GR20000400152T patent/GR3032458T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE59800046D1 (de) | 1999-12-23 |
| CZ297951B6 (cs) | 2007-05-02 |
| SK109299A3 (en) | 2000-08-14 |
| PL190293B1 (pl) | 2005-11-30 |
| PL335249A1 (en) | 2000-04-10 |
| HUP0001094A3 (en) | 2001-02-28 |
| WO1998035679A1 (de) | 1998-08-20 |
| CZ289699A3 (cs) | 2000-02-16 |
| SK282549B6 (sk) | 2002-10-08 |
| ATE186643T1 (de) | 1999-12-15 |
| HUP0001094A2 (hu) | 2000-09-28 |
| EP0880352B1 (de) | 1999-11-17 |
| EP0880352A2 (de) | 1998-12-02 |
| ES2141631T3 (es) | 2000-03-16 |
| GR3032458T3 (en) | 2000-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU224964B1 (en) | Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone | |
| EP0858329B1 (fr) | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation | |
| AU604061B2 (en) | Drug compositions stabilized against oxidation | |
| US5703080A (en) | Method for stabilizing duocarmycin derivatives | |
| KR20110122217A (ko) | 항진균성 약제학적 조성물 | |
| RU2311900C2 (ru) | Содержащие действующее вещество пленочные препараты с повышенной химической стойкостью и способы их получения | |
| HK1084582A1 (en) | Stable solid medicinal composition for oral administration | |
| HU220632B1 (hu) | Ibuprofent tartalmazó pezsgő gyógyászati kompozíció, és eljárás annak előállítására | |
| WO1989011855A1 (en) | Stable pharmaceutical composition | |
| JP3195360B2 (ja) | チアガビン塩酸塩を含有する医薬組成物およびその製法 | |
| US4621075A (en) | Gel-form topical antibiotic compositions | |
| EP1543826B1 (en) | Concentrated aqueous solution of ambroxol | |
| US7699987B2 (en) | Stabilized formulation | |
| US20070077261A1 (en) | Compositions and method for enhancing the solubility of ascorbic acid using solubilization enhancers | |
| SK278421B6 (en) | Parenterally applicable pharmaceutical composition containing bis-indole alkaloid and preparation method thereof | |
| WO2006126825A1 (en) | Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection | |
| JP2007106736A (ja) | 注射用の医薬組成物 | |
| HU181940B (en) | Process for producing solutions of vincane derivatives for parentheral application | |
| WO1994007493A1 (en) | Stabilized compositions containing 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxyaldehyde-o-methyl-oxime | |
| RU2173996C2 (ru) | Фармацевтическая композиция, содержащая гидрохлорид тиагабина, и способ ее получения | |
| RU2296765C1 (ru) | Способ получения солей n4-пропилаймалиния с карбоновыми кислотами, стабильный раствор n4-пропилаймалиния гидромалоната и способ его получения | |
| Dąbrowska-Maś et al. | New approaches to the synthesis of diclofenac choline | |
| GB2561355A (en) | Pharmaceutical composition and a method for manufacturing the same | |
| CA2532110A1 (en) | Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations | |
| WO2017129772A1 (en) | Stable pharmaceutical compositions of temsirolimus |